Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + albumin-bound paclitaxel + carboplatin + trastuzumab as neoadjuvant therapy for HER2-positive early or locally advanced breast cancer
ChiCTR2100043523Phase 2Recruiting
- Sponsor
- Breast Oncology Center
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pyrotinib, trastuzumab, paclitaxel and carboplatin in breast cancer, sponsored by Breast Oncology Center. Primary endpoint: Total pathological complete response. Started Dec 2020; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100043523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043523.